CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

Deal-hungry Lilly strikes up to $2.9B immuno play for Merida

Positive
AI Analysis

Summary

Eli Lilly is acquiring Merida Biosciences for up to $2.9B to gain a precision degradation platform for therapies targeting pathologic antibodies in allergic and autoimmune diseases.

Importance:7/10
Sentiment:
0.70
M&Aacquisitionprecision degradation platformautoimmune diseasesallergic diseasespathologic antibodies
Related Companies

Read the original article

Published by BioSpace on August 31, 2026 1:03 PM

Read Original